Cargando…

Successful use of an antithrombin for heparin resistance with andexanet alfa

Detalles Bibliográficos
Autores principales:	Honda, Jun, Itakura, Yuya, Tanaka, Shiori, Inoue, Satoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188801/ https://www.ncbi.nlm.nih.gov/pubmed/37193808 http://dx.doi.org/10.1186/s40981-023-00619-7

Ejemplares similares

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

Cardiac tamponade developing during Trousseau's syndrome with pulmonary embolism
por: Itakura, Yuya, et al.
Publicado: (2023)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

How will UK hospitals use andexanet alfa? A review of local protocols
por: Glancy, Paula, et al.
Publicado: (2023)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin
por: Wada, Hideo, et al.
Publicado: (2023)

A case of markedly enlarged blood vessels in the intercostal and paravertebral spaces in a patient with severe liver failure
por: Yoshida, Keisuke, et al.
Publicado: (2023)

An Antithrombin-Heparin Complex Increases the Anticoagulant Activity of Fibrin Clots
por: Smith, Lesley J., et al.
Publicado: (2008)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
por: Hu, Tiffany Y, et al.
Publicado: (2016)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
por: Rauch, Sebastian, et al.
Publicado: (2022)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report
por: Brenner, Brian, et al.
Publicado: (2022)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022)

Obstacles to ultrasound-guided internal jugular vein central venous catheter insertion
por: Honda, Jun, et al.
Publicado: (2023)

Intraprocedural Thrombotic Events during Percutaneous Coronary Intervention Due to Acquired Antithrombin Deficiency-related Heparin Resistance Successfully Treated with Antithrombin Gamma Supplementation
por: Yokoi, Masashi, et al.
Publicado: (2022)

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Proper diagnosis of antithrombin III deficiency
por: Özdemir, Zehra Narlı, et al.
Publicado: (2017)

Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital
por: Sobolewski, Kristine A., et al.
Publicado: (2021)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
por: Murao, Atsushi, et al.
Publicado: (2022)

Cerebral infarction following administration of andexanet alfa for anticoagulant reversal in a patient with traumatic acute subdural hematoma
por: Nagai, Arata, et al.
Publicado: (2023)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan B, et al.
Publicado: (2021)

Antithrombin, COVID-19, and Fresh Frozen Plasma Treatment
por: Mungmungpuntipantip, Rujitttika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gf8g9aknkcvohhi5ugp12hrsc8